Development of the Virtual Unified Huntington's Disease Rating Scale

Open to people ages 18 years and up

1. Are male or female and 18 years or older at the time of signing the informed consent
2. Are able and willing to provide written informed consent
3. Are English speaking
4. Currently exhibit motor signs and symptoms of Huntington Disease
5. Have a genetic diagnosis of HD with an expanded CAG repeat (greater than or equal to 36) in the huntingtin (HTT) gene at or before Screening/Baseline visit from a validated laboratory
6. Have oral and written communication skills that are sufficient/adequate to complete all cognitive assessments
7. Are ambulatory, but may use any assistive device or require help
8. Are able to maintain stable medications for 30 days prior to Screening/Baseline through the second in-person visit

9. Have a study partner available to help with technology and set-up and to attend all study visits

   10. Have the ability to get email on the device used for the study

1. Are unable to complete cognitive or functional assessments due to inability to communicate
2. Are unable to obtain satisfactory internet connection (i.e., internet connection must be stable and support the audio and video needs without freezing or interruption) at home or designated location, even with provided equipment
3. Have inadequate space at home to assess 10 steps for gait assessments
4. Have active suicidal ideation endorsed with a score of 4 (Active Suicidal Ideation with Some Intent to Act, without Specific Plan) if the ideation occurred within 1 year of Screening or 5 (Active Suicidal Ideation with Specific Plan and Intent) on the C-SSRS if the attempt or acts were performed within 1 year of Screening/Baseline, or participants who, in the opinion of the Site Investigator (SI), present a serious risk of suicide.
5. Have received gene therapy or an investigational drug within 30 days or 5 half-lives, whichever is longer, of the Screening/Baseline visit or plan to use an investigational drug during this study.